LAG-3-binding molecules and methods of use thereof

US11072653B2 · kind B2 · utility

Assignee

• Macrogenics, Inc. · US

Inventors

• Ross La Motte-Mohs · Boyds, US
• Kalpana Shah · Rockville, US
• Douglas H. Smith · Boothwyn, US
• Leslie S. Johnson · Travilah, US
• Paul A. Moore · North Potomac, US
• Ezio Bonvini · Potomac, US
• Scott Koenig · Rockville, US

Key dates

• Filing date: Jun 7, 2016
• Grant date: Jul 27, 2021
• Expiry date: Jul 28, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/21
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.